RecruitingPHASE1, PHASE2NCT04625907
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Studying Rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Birmingham
- Principal Investigator
- Meriel JenneyChief Investigator
- Intervention
- Irinotecan(drug)
- Enrollment
- 1672 enrolled
- Eligibility
- All sexes
- Timeline
- 2020 – 2030
Study locations (30)
- Queensland Children's Hospital, Brisbane, Australia
- Chris O'brien Lifehouse, Camperdown, Australia
- Monash Children's Hospital, Clayton, Australia
- Peter Maccallum Cancer Centre, Melbourne, Australia
- Royal Childrens Hospital Melbourne, Melbourne, Australia
- John Hunter Children's Hospital, New Lambton Heights, Australia
- Perth Children's Hospital, Perth, Australia
- Sydney Children's Hospital, Sydney, Australia
- The Childrens Hospital At Westmead, Sydney, Australia
- Westmead Hospital, Westmead, Australia
- Princess Alexandra Hospital, Woolloongabba, Australia
- Kepler University Clinic Linz, Linz, Austria
- St Anna Childrens Hospital, Vienna, Austria
- Cliniques Universitaires Saint Luc, Brussels, Belgium
- Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04625907 on ClinicalTrials.govOther trials for Rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07449949A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus RhabdomyosarcomaEye & ENT Hospital of Fudan University
- RECRUITINGPHASE1NCT06865664FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory RhabdomyosarcomaNational Cancer Institute (NCI)
- RECRUITINGNCT06924463Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass SpectrometryLille University
- RECRUITINGPHASE1, PHASE2NCT06456892Effectiveness of Pucotenlimab Combined With Standard Chemotherapy RegimenSun Yat-sen University
- RECRUITINGPHASE2NCT06023641Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk DiseaseSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT05457829Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical StudySun Yat-sen University
- RECRUITINGPHASE1, PHASE2NCT04796012VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid TumorsUniversity of Texas Southwestern Medical Center
- RECRUITINGPHASE1NCT04995003HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaBaylor College of Medicine